Reference number : GC-2017-Q4-00512, amendment number : , agreement type : G, recipient legal name : Dudding, Travis (Brock University), recipient country : CA, recipient province : nan, recipient city : Ontario, recipient postal code : nan, program name english : Engage Grants for universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : A promising approach to drug formulation is the design of cocrystals to improve the physicochemical_x000D_
properties of active pharmaceutical ingredients (APIs), while maintaining its therapeutic activity. Cocrystals_x000D_
have the ability to alter certain API characteristics, such as solubility, dissolution, and stability that play a major_x000D_
role in overcoming problems associated with drug delivery and bioavailability. However, current approaches_x000D_
for designing API co-crystals, rely on the use of time-consuming and expensive experimental based co-crystal_x000D_
screens._x000D_
To overcome these limitations, Apotex Pharmachem, Canada's largest developer and manufacturer of generic_x000D_
pharmaceuticals seeks to develop high-throughput (HT) screening approaches for designing API co-crystals. In_x000D_
collaboration with Brock University, the proposed research aims to develop a novel computer-based approach_x000D_
to co-crystal design by using a combination of statistical and quantum mechanical modelling methods. These_x000D_
project outcomes will be the first step towards accelerating the formulation development process and allow for_x000D_
the reliable prediction of API co-crystal stability. This has wide ranging implications for Apotex to generate_x000D_
innovative pharmaceuticals and various dosage forms, thus further establishing Canada's place as global leader_x000D_
in science, innovation, and technology., program purpose french : A promising approach to drug formulation is the design of cocrystals to improve the physicochemical_x000D_
properties of active pharmaceutical ingredients (APIs), while maintaining its therapeutic activity. Cocrystals_x000D_
have the ability to alter certain API characteristics, such as solubility, dissolution, and stability that play a major_x000D_
role in overcoming problems associated with drug delivery and bioavailability. However, current approaches_x000D_
for designing API co-crystals, rely on the use of time-consuming and expensive experimental based co-crystal_x000D_
screens._x000D_
To overcome these limitations, Apotex Pharmachem, Canada's largest developer and manufacturer of generic_x000D_
pharmaceuticals seeks to develop high-throughput (HT) screening approaches for designing API co-crystals. In_x000D_
collaboration with Brock University, the proposed research aims to develop a novel computer-based approach_x000D_
to co-crystal design by using a combination of statistical and quantum mechanical modelling methods. These_x000D_
project outcomes will be the first step towards accelerating the formulation development process and allow for_x000D_
the reliable prediction of API co-crystal stability. This has wide ranging implications for Apotex to generate_x000D_
innovative pharmaceuticals and various dosage forms, thus further establishing Canada's place as global leader_x000D_
in science, innovation, and technology., agreement title english : Computation methods for co-crystal screening of APIs, agreement title french : Computation methods for co-crystal screening of APIs, agreement number : EGP, agreement value : 25000.0, agreement start date : 2018-03-07, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada